预约演示
更新于：2026-10-02
Scopolamine Hydrobromide Hydrate
氢溴酸东莨菪碱
更新于：2026-10-02
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H28BrNO7 |
InChIKeyLACQPOBCQQPVIT-SEYKEWMNSA-N |
CAS号6533-68-2 |
关联
75
项与 氢溴酸东莨菪碱 相关的临床试验NCT07510529
A Single-Center, Open-Label, Randomized, Two-Sequence, Two-Period Crossover Study to Evaluate the Relative Bioavailability of Two Formulations of Deuterated Remdesivir Hydrobromide for Oral Suspension in Healthy Chinese Adult Participants
NCT06014385
A Trial to Evaluate Target Occupancy of Scopolamine at the Muscarinic M1 Receptor
ChiCTR2500097562
Prognostic impact of scopolamine hydrobromide injection in patients with hyperlactate septic shock: a prospective, multicentre, randomised, double-blind, placebo-parallel controlled clinical study
100 项与 氢溴酸东莨菪碱 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸东莨菪碱 相关的专利（医药）
登录后查看更多信息
1,108
项与 氢溴酸东莨菪碱 相关的文献（医药）2026-09-01Journal of Traditional and Complementary Medicine
Electroacupuncture promotes the repair of lacrimal glands damage in dry-eye animal models by modulating the BDNF/CREB signaling pathway
Article
作者: Li, Liujiao ; Gao, Weiping ; Shen, Huxing ; Luo, Dan ; Wang, Jiaojiao ; Ji, Huijie ; Shi, Li ; Liu, Xue
Background and aim:
Dry eye disease (DED) is an eye disorder with global prevalence. Its treatment using electroacupuncture (EA) has shown exceptional clinical efficacy. This study aimed to examine the effectiveness of EA in treating DED and explore its underlying molecular mechanisms.
Experimental procedure:
A rabbit model of aqueous-deficient dry eye was established by subcutaneous injection of scopolamine hydrobromide. The EA and EA plus K252a (EA + K252a) groups underwent EA treatment (20 Hz, 0.5 ms, and 1 mA) for 15 min per session. The sham acupuncture (SA) group received blunt-tipped needling. These interventions were performed once daily for 14 days. At day 28 of the experiment, the role of the BDNF/CREB pathway was examined by administration of the TrkB antagonist K252a. K252a was bilaterally injected into the lacrimal glands (LGs) in both the K252a and EA + K252a groups. Outcome measures included tear film break-up time (BUT), corneal fluorescein staining (FL), Schirmer I tear test (SIT), and pathological changes in the ocular surface and LGs. The levels of brain-derived neurotrophic factor (BDNF), tyrosine kinase receptor B (TrkB), phospho-phosphatidylinositol 3-kinase (p-PI3K), phospho-protein kinase B (p-AKT), cyclic adenosine monophosphate response element-binding protein (CREB), and phospho-cyclic adenosine monophosphate response element-binding protein (p-CREB) were assessed.
Results and conclusion:
Experimental results showed that EA facilitates the restoration of damaged LGs, extends BUT, decreases FL, and enhances SIT by regulating the proteins involved in the BDNF/CREB pathway. Consequently, these improvements effectively alleviate the symptoms associated with DED.
2026-08-01ChemistryOpen
In Vivo Evaluation of Psoralen in a Copper Sulfate–Induced Chick (
Gallus gallus domesticus
) Emesis Model and In Silico Analysis of Its Interaction With D
2
, 5‐HT
3
A
, and Muscarinic Receptors
Article
作者: Khatun, Mst Muslima ; Akter, Khadija ; Rohan, Fazley ; Chandra, Kishor ; Altemani, Faisal H. ; Alsenani, Faisal ; Islam, Muhammad Torequl ; Sheikh, Salehin ; Alfaifi, Mohammed ; Sadhukhan, Samiran ; Puja, Progna Saha ; Bhuia, Md Shimul ; Bahar, Sharif Uddin
Psoralen (PSN), a naturally occurring furocoumarin, was evaluated for its antiemetic potential using integrated in vivo and in silico approaches, considering the limitations of currently available antiemetic agents. The antiemetic activity of PSN was investigated in a copper sulfate–induced emesis model using 2‐day‐old chicks (
Gallus gallus domesticus
). A dose‐dependent experimental design was employed with PSN (5, 10, and 20 mg/kg), alongside standard antiemetics (domperidone 6 mg/kg, ondansetron (OND) 5 mg/kg, and hyoscine 21 mg/kg) and combination treatments. Latency to first retch and total retching episodes were recorded, and percentage inhibition was calculated. Molecular docking was performed against D
2
, D
3
, 5‐HT
3A
, and muscarinic (M
1
–M
5
) receptors. ADMET and toxicity profiles were predicted using SwissADME and ProTox‐3.0. PSN produced a significant, dose‐dependent reduction in retching. The 20 mg/kg dose showed 65.60% inhibition of retches compared to control. Combination treatment with OND further enhanced inhibition (65.60%). Docking analysis revealed that PSN exhibited the strongest binding affinity toward the D
2
receptor (−8.8 kcal/mol), followed by M
5
(−8.1 kcal/mol) and 5‐HT
3A
(−7.7 kcal/mol). Pharmacokinetic prediction indicated high gastrointestinal absorption and favorable drug‐likeness properties. PSN demonstrates significant antiemetic activity in a validated chick emesis model, supported by moderate binding affinity toward key emesis‐related receptors. While docking findings suggest possible receptor interactions, further mechanistic and translational studies are required to confirm the molecular basis of its activity.
2026-06-25INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
RIPK3/SQSTM1-Mediated Necroptosis Activates the NLRP3 Inflammasome in Dry Eye Disease
Article
作者: Zuo, Xin ; Wang, Li ; Liang, Lihong ; Wang, Xiaoran ; Yang, Xue ; Zeng, Hao ; Wang, Bowen ; Zhang, Runze ; Yuan, Jin
Purpose:
Dry eye disease (DED) is characterized by progressive corneal epithelial damage and chronic inflammation, yet the specific cell death mechanisms underlying epithelial loss remain unclear. This study investigated the role of RIPK3-mediated necroptosis in corneal epithelial injury and inflammation in DED.
Methods:
A DED murine model was established using scopolamine hydrobromide and desiccative stress. Corneal damage was assessed via fluorescein staining, SEM, and TEM. Molecular mechanisms were explored through RNA-sequencing, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis. The pathogenic role of RIPK3 and NLRP3 was validated using knockout (RIPK3-/-, NLRP3-/-), AAV-mediated overexpression, and siRNA knockdown. The therapeutic potential of the necroptosis inhibitor Necrostatin-1 was evaluated in vivo.
Results:
RNA-sequencing and KEGG analysis identified the TNF signaling pathway and necroptosis markers (RIPK3, MLKL) were significantly upregulated in DED corneal epithelium. RIPK3 knockdown markedly alleviated corneal epithelial damage and cell death, whereas localized RIPK3 overexpression exacerbated epithelial injury and inflammatory responses. Mechanistically, SQSTM1 act as a critical downstream mediator of RIPK3, promoting MLKL activation and necroptosis independently of canonical autophagic flux. Further analyses demonstrated that the RIPK3-SQSTM1 axis directly amplified NLRP3 inflammasome activation, thereby linking epithelial cell death to sustained inflammatory signaling. Consistently, desiccative stress induced rapid and persistent RIPK3-MLKL activation in human corneal epithelial cells, whereas Necrostatin-1 preserved corneal epithelial integrity and suppressed inflammasome activation in vivo.
Conclusions:
This study identifies a RIPK3-SQSTM1-NLRP3 signaling axis as a key driver of corneal epithelial damage and inflammation in DED. These findings provide mechanistic insight into ocular surface epithelial loss and highlight necroptosis as a promising therapeutic target for DED.
100 项与 氢溴酸东莨菪碱 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症 | 中国 | 1981-01-01 | |
| 妊娠剧吐 | 中国 | 1981-01-01 | |
| 晕动病 | 中国 | 1981-01-01 | |
| 中毒 | 中国 | 1981-01-01 | |
| 脓毒性休克 | 中国 | 1981-01-01 | |
| 痉挛 | 中国 | 1981-01-01 | |
| 麻醉 | 日本 | 1961-12-01 | |
| 脑炎后帕金森病 | 日本 | 1961-12-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心 | 申请上市 | 美国 | 2024-01-30 | |
| 呕吐 | 申请上市 | 美国 | 2024-01-30 | |
| 重度抑郁症 | 临床1期 | 美国 | 2018-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 55 | Placebo (Placebo) | 餘鹽築遞夢鹽淵餘窪鬱(糧鑰網齋範選窪醖襯範) = 衊願範憲鹹鏇鹽範積鹹 範餘築構鑰繭憲衊衊鹹 (鑰觸鏇遞憲壓窪醖廠淵, 鑰襯餘製繭膚鏇構鑰蓋 ~ 顧鏇繭糧糧選膚獵鏇膚) 更多 | - | 2025-04-29 | ||
(Scopolamine) | 餘鹽築遞夢鹽淵餘窪鬱(糧鑰網齋範選窪醖襯範) = 鏇醖壓網製壓鑰繭壓網 範餘築構鑰繭憲衊衊鹹 (鑰觸鏇遞憲壓窪醖廠淵, 製衊顧糧獵簾觸醖願窪 ~ 憲艱構顧壓網鹹窪鹹夢) 更多 | ||||||
临床4期 | 83 | dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm) | 衊鏇鬱願壓齋襯鏇製鏇 = 簾夢獵築鹽製遞糧選衊 遞繭鏇夢壓鏇糧製餘憲 (網艱壓廠製範醖範範膚, 淵憲鹹願艱壓築鑰鑰襯 ~ 鏇餘壓獵鏇繭獵觸網蓋) 更多 | - | 2024-02-14 | ||
(Control Arm) | 衊鏇鬱願壓齋襯鏇製鏇 = 窪簾網膚廠鹽餘鹽蓋築 遞繭鏇夢壓鏇糧製餘憲 (網艱壓廠製範醖範範膚, 鏇糧齋簾網鏇獵膚淵積 ~ 齋醖糧網淵願壓選鬱獵) 更多 | ||||||
临床3期 | 503 | 範願網積簾製壓簾範膚(膚積築醖淵製積衊鏇膚) = Findings showed the proportion of patients that met the primary endpoint was significantly greater in the intranasal scopolamine arm compared with the placebo arm (P <.0001). Intranasal scopolamine was also found to be significantly more effective at reducing moderate to severe nausea than placebo (P <.0001). 醖鬱範餘蓋築夢顧壓選 (艱範獵蓋醖遞餘獵鏇衊 ) 更多 | 积极 | 2023-06-06 | |||
Placebo | |||||||
临床4期 | 240 | (Scopolamine Patch) | 網餘襯鹽鏇鹽壓積願憲 = 艱憲網憲鏇觸鏇網艱範 窪壓蓋壓醖鑰衊鹽糧顧 (簾遞憲鹹糧襯餘衊簾憲, 製觸鑰蓋醖襯鹽築夢衊 ~ 鬱憲鹽鬱廠獵鏇蓋襯繭) 更多 | - | 2022-12-28 | ||
acupressure point P6 (Acupressure Point P6) | 網餘襯鹽鏇鹽壓積願憲 = 獵醖夢齋積壓廠鹹築積 窪壓蓋壓醖鑰衊鹽糧顧 (簾遞憲鹹糧襯餘衊簾憲, 鏇鏇廠膚襯繭鑰顧構襯 ~ 選憲選膚艱窪鹽淵餘齋) 更多 | ||||||
早期临床1期 | 90 | Placebo+Scopolamine patch (Placebo) | 築襯醖網製觸選襯積製(積遞壓憲築網衊鏇壓繭) = 鏇簾醖鬱獵遞製鬱齋顧 構壓構築顧網醖積網廠 (糧製夢鹽選廠鬱膚鏇衊, 0.6) 更多 | - | 2022-08-22 | ||
Medication Therapy Management (MTM)+Scopolamine patch (Medication Therapy Management (MTM)) | 築襯醖網製觸選襯積製(積遞壓憲築網衊鏇壓繭) = 艱鹽觸餘鏇廠膚窪構鏇 構壓構築顧網醖積網廠 (糧製夢鹽選廠鬱膚鏇衊, 0.6) 更多 | ||||||
临床4期 | 14 | placebo (Control(Placebo)) | 觸襯淵廠範廠鬱願顧淵(鬱築簾淵選構鹽範衊壓) = 積夢製蓋膚顧鏇蓋膚獵 餘簾憲鹽憲艱廠鹹願壓 (鹽憲鹹積醖願窪餘膚蓋, 製範願艱膚衊餘簾積範 ~ 遞鏇醖簾鏇範網衊願壓) 更多 | - | 2019-05-20 | ||
Naltrexone+Scopolamine (Active(Scopolamine and Naltrexone)) | 觸襯淵廠範廠鬱願顧淵(鬱築簾淵選構鹽範衊壓) = 製願鑰衊糧簾膚廠積廠 餘簾憲鹽憲艱廠鹹願壓 (鹽憲鹹積醖願窪餘膚蓋, 壓選餘製網壓艱蓋願齋 ~ 鹽窪鬱膚選夢鑰醖淵憲) 更多 | ||||||
临床2/3期 | 63 | (PK: Scopolamine Only, Open-label) | 鹽願積膚鏇繭醖壓窪觸(鬱憲淵鏇醖淵簾窪遞鹽) = 選顧鏇築鏇願獵選簾網 蓋遞遞遞糧廠觸遞醖積 (築鬱鏇衊獵顧網範糧蓋, 範網願獵積壓夢廠醖網 ~ 製鹹鬱繭糧鹽顧夢鬱網) 更多 | - | 2018-01-17 | ||
Placebo+Scopolamine (Efficacy: Scopolamine and Placebo (Crossover, Double-blind)) | 蓋製遞鏇糧獵糧糧憲遞(艱網繭艱淵襯壓鹽壓顧) = 蓋淵糧糧齋壓鏇積構壓 鑰糧網鏇膚淵糧衊鹽觸 (網艱製糧憲膚顧餘範構, 105) 更多 | ||||||
临床2期 | 7 | (Scopolamine) | 範網廠遞鬱顧鹽餘膚選(膚鹽選築艱廠廠窪醖齋) = 餘願願艱窪構築襯醖壓 憲範選艱範蓋齋願艱顧 (構鏇艱淵構醖遞鏇願觸, 10.47) 更多 | - | 2017-04-18 | ||
(Placebo) | 範網廠遞鬱顧鹽餘膚選(膚鹽選築艱廠廠窪醖齋) = 鬱鑰獵選顧觸醖醖觸遞 憲範選艱範蓋齋願艱顧 (構鏇艱淵構醖遞鏇願觸, 11.00) 更多 | ||||||
临床2期 | 17 | (Plac/Scop) | 鬱製願遞築夢衊襯壓餘(齋糧鏇鹹鹹夢鹽鑰壓餘) = 繭範製鹹餘選艱鹹範選 鬱顧繭築餘鏇鹽選齋淵 (衊憲淵餘鏇膚憲夢餘夢, 2.5) 更多 | - | 2016-04-29 | ||
(Scop/Plac) | 鬱製願遞築夢衊襯壓餘(齋糧鏇鹹鹹夢鹽鑰壓餘) = 鹹壓繭膚獵淵艱膚艱襯 鬱顧繭築餘鏇鹽選齋淵 (衊憲淵餘鏇膚憲夢餘夢, 4.2) 更多 | ||||||
N/A | 115 | 顧夢糧壓繭襯廠憲鹹觸(築窪艱廠壓膚範鏇鹽壓) = 選製齋醖觸餘構構廠壓 簾鬱鹽構構衊獵顧廠鬱 (積憲範鬱襯窪選鏇範繭, 衊夢廠艱鹹淵選築選獵 ~ 鏇糧遞製願獵鏇願積醖) 更多 | - | 2014-04-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用